COYA / Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Keystone Symposia Meeting for Neurode

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing more_horizontal

Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, includ more_horizontal

Shares of Coya Therapeutics Inc. COYA, +3.33% gained 12% premarket on Wednesday after the clinical-stage biotech company released new data from a stud more_horizontal

Recently, IPO'd Coya has just reported cognition-improving and cognition-stabilizing results in an open label study in Alzheimer's patients with Coya more_horizontal

If you are looking for stocks that are well positioned to maintain their recent uptrend, Coya Therapeutics, Inc. (COYA) could be a great choice. It is more_horizontal

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing more_horizontal

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing more_horizontal

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing more_horizontal